Vertas strives to give back to our communities, be good corporate citizens and respect our environment.
Each year, the Vertas Group commits to raise money for charity. During 2016/17, we raised money for East Anglian Air Ambulance; donating over £4000 to the local charity.
Throughout 2017 to early 2019, our Charity of the Year was Cancer Research UK. At our third annual ‘Making the Difference’ awards on Friday 2nd March, group CEO Ian Surtees presented a cheque for £8,500 to Cancer Research. Along with this, we also raised £2,000 during our awards evening and a further £9,400 across three Director’s challenges that saw our Directors and their teams of willing Vertas volunteers, climb mountains, ride across the country and jump from aeroplanes.
We will continue our fundraising for Cancer Research UK over 2019 and into 2020. Our group CEO Ian Surtees presented a cheque for £12,731.67 to the charity along with raising £1,375 on the evening. We have some more fantastic challenges facing our colleagues this year where we hope to raise further funds for this amazing charity.
To date, we have raised £22,606.67 for Cancer Research.
Keep an eye on this page for our latest charity challenges and successes.
In 2018, we joined forces with Ipswich Town Football Club, East of England Co-op, Suffolk County Council and the East Anglian Daily Times to encourage children and schools to sign up to The Daily Mile. This on-going initiative, called East Anglian Go Kids, aims to improve the physical, emotional, social health and wellbeing of young people.
“The enthusiasm and creativity shown by the Vertas team in organising and delivering fun and hugely successful fundraising activities is extremely impressive and shows no sign of slowing down. Over the past two years, Vertas has raised over £21k and we would like to thank everyone for all their efforts in making such a significant contribution to research. Cancer Research UK receives no Government funding so our life-saving work is entirely dependent on individual and corporate supporters.”
Gill Burgess, Cancer Research UK